Survival with radical mastectomy for invasive breast cancer
Descripción del Articulo
To compare the rates of long-term survival according to various clinical and pathological and therapeutic factors and determine the ten-year survival rates and recurrence after radical mastectomy classic (MRC) and modified radical mastectomy (MRM). MATERIALS AND METHODS: We retrospectively reviewed...
| Autores: | , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2015 |
| Institución: | Sociedad Peruana de Obstetricia y Ginecología |
| Repositorio: | Revista SPOG - Revista Peruana de Ginecología y Obstetricia |
| Lenguaje: | español |
| OAI Identifier: | oai:ojs.spog:article/1373 |
| Enlace del recurso: | http://www.spog.org.pe/web/revista/index.php/RPGO/article/view/1373 |
| Nivel de acceso: | acceso abierto |
| id |
2304-5132_f0b8aaee214dd3bdee99e59b74c5017d |
|---|---|
| oai_identifier_str |
oai:ojs.spog:article/1373 |
| network_acronym_str |
2304-5132 |
| repository_id_str |
. |
| network_name_str |
Revista SPOG - Revista Peruana de Ginecología y Obstetricia |
| dc.title.none.fl_str_mv |
Survival with radical mastectomy for invasive breast cancer Sobrevida con mastectomía radical en cáncer de mama invasor |
| title |
Survival with radical mastectomy for invasive breast cancer |
| spellingShingle |
Survival with radical mastectomy for invasive breast cancer Díaz, Juan |
| title_short |
Survival with radical mastectomy for invasive breast cancer |
| title_full |
Survival with radical mastectomy for invasive breast cancer |
| title_fullStr |
Survival with radical mastectomy for invasive breast cancer |
| title_full_unstemmed |
Survival with radical mastectomy for invasive breast cancer |
| title_sort |
Survival with radical mastectomy for invasive breast cancer |
| dc.creator.none.fl_str_mv |
Díaz, Juan Salgado, Lucero Roeder, Rafael |
| author |
Díaz, Juan |
| author_facet |
Díaz, Juan Salgado, Lucero Roeder, Rafael |
| author_role |
author |
| author2 |
Salgado, Lucero Roeder, Rafael |
| author2_role |
author author |
| dc.contributor.none.fl_str_mv |
|
| dc.description.none.fl_txt_mv |
To compare the rates of long-term survival according to various clinical and pathological and therapeutic factors and determine the ten-year survival rates and recurrence after radical mastectomy classic (MRC) and modified radical mastectomy (MRM). MATERIALS AND METHODS: We retrospectively reviewed the medical records of 72 patients with operable invasive breast carcinoma with negative axilla (n = 38) or positive (n = 34), treated with MRC (n = 57) or MRM (n = 15) Belen Hospital, Trujillo, Peru, from 1 January 1966 to December 31, 1995. RESULTS: The mean age was 47.6 ± 9.5 years (range 30-70 years). The average disease duration was 9 months (range 0.3 to 156 months). The most frequent symptoms or signs were present tumor (100%) and breast (37.5%) pain. The ten-year survival rates in patients treated with MRC and MRM, according to the actuarial Kaplan-Meier method were 58% and 54%, respectively (p = NS). There was no significant difference in the rate of ten-year survival between the group of MRC and MRM considering tumor size, number of positive regional nodes, axillary committed, pathological stage and type of treatment. In patients with negative axillary lymph there was a significant improvement in the ten-year survival when treated with MRC with MRM (68% versus 38%, p <0.05). Decadal regional local recurrence rates, and distance MRC group were 21%, 1.8% and 24.6% respectively, while the MRM group decadal rates of local, regional and distant recurrence were 13 , 3 10% and 26%, 7%, respectively (p = NS). CONCLUSIONS: In patients with operable breast carcinoma, the ten-year survival is similar when they are treated with MRC and MRM; however in patients with negative axillary nodes, the ten-year survival is favorably influenced by the MRC. OBJETIVOS: Comparar las tasas de sobrevida a largo plazo según diversos factores clínico-patológicos y terapéuticos y determinar las tasas de sobrevida y recurrencia decenal luego de mastectomía radical clásica (MRC) y mastectomía radical modificada (MRM). MATERIAL Y MÉTODOS: Revisamos retrospectivamente las historias clínicas de 72 pacientes con carcinoma de mama invasor operable con axila negativa (n=38) o positiva (n=34), tratadas con MRC(n=57) o MRM (n=15) en el Hospital Belén, Trujillo, Perú, desde el 1° de enero de 1966 al 31 de diciembre de 1995. RESULTADOS: La edad media fue 47,6 ± 9,5 años (límites, 30 a 70 años). El tiempo medio de enfermedad fue 9 meses (límites, 0,3 a 156 meses). Los síntomas o signos más frecuentes fueron presencia del tumor (100%) y dolor mamario (37,5%). Las tasas de sobrevida decenal en las pacientes tratadas con MRC y MRM, según el método actuarial de Kaplan-Meier, fueron 58% y 54%, respectivamente (p=NS). No hubo diferencia significativa en la tasa de sobrevida decenal entre el grupo de MRC y MRM al considerar el tamaño tumoral, número de ganglios regionales positivos, nivel axilar comprometido, estadio patológico y tipo de tratamiento. En las pacientes con ganglios axilares negativos hubo una mejora significativa en la sobrevida decenal cuando fueron tratadas con MRC que con MRM (68% contra 38%, p < 0,05). Las tasas decenales de recurrencia local, regional y a distancia en el grupo de MRC, fueron 21 %, 1,8% y 24,6%, respectivamente, mientras que el grupo de MRM las tasas decenales de recurrencia local, regional y a distancia fueron 13,3% 10% y 26, 7%, respectivamente (p=NS). CONCLUSIONES: En pacientes con carcinoma de mama operable, la sobrevida decenal es similar cuando éstas son tratadas con MRC y MRM; sin embargo en las pacientes con ganglios axilares negativos, la sobrevida decenal es influida favorablemente por la MRC. |
| description |
To compare the rates of long-term survival according to various clinical and pathological and therapeutic factors and determine the ten-year survival rates and recurrence after radical mastectomy classic (MRC) and modified radical mastectomy (MRM). MATERIALS AND METHODS: We retrospectively reviewed the medical records of 72 patients with operable invasive breast carcinoma with negative axilla (n = 38) or positive (n = 34), treated with MRC (n = 57) or MRM (n = 15) Belen Hospital, Trujillo, Peru, from 1 January 1966 to December 31, 1995. RESULTS: The mean age was 47.6 ± 9.5 years (range 30-70 years). The average disease duration was 9 months (range 0.3 to 156 months). The most frequent symptoms or signs were present tumor (100%) and breast (37.5%) pain. The ten-year survival rates in patients treated with MRC and MRM, according to the actuarial Kaplan-Meier method were 58% and 54%, respectively (p = NS). There was no significant difference in the rate of ten-year survival between the group of MRC and MRM considering tumor size, number of positive regional nodes, axillary committed, pathological stage and type of treatment. In patients with negative axillary lymph there was a significant improvement in the ten-year survival when treated with MRC with MRM (68% versus 38%, p <0.05). Decadal regional local recurrence rates, and distance MRC group were 21%, 1.8% and 24.6% respectively, while the MRM group decadal rates of local, regional and distant recurrence were 13 , 3 10% and 26%, 7%, respectively (p = NS). CONCLUSIONS: In patients with operable breast carcinoma, the ten-year survival is similar when they are treated with MRC and MRM; however in patients with negative axillary nodes, the ten-year survival is favorably influenced by the MRC. |
| publishDate |
2015 |
| dc.date.none.fl_str_mv |
2015-07-15 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://www.spog.org.pe/web/revista/index.php/RPGO/article/view/1373 10.31403/rpgo.v45i1373 |
| url |
http://www.spog.org.pe/web/revista/index.php/RPGO/article/view/1373 |
| identifier_str_mv |
10.31403/rpgo.v45i1373 |
| dc.language.none.fl_str_mv |
spa |
| language |
spa |
| dc.relation.none.fl_str_mv |
http://www.spog.org.pe/web/revista/index.php/RPGO/article/view/1373/1326 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Sociedad Peruana de Obstetricia y Ginecología |
| publisher.none.fl_str_mv |
Sociedad Peruana de Obstetricia y Ginecología |
| dc.source.none.fl_str_mv |
Revista Peruana de Ginecología y Obstetricia; Vol. 45, Núm. 2 (1999); 97-105 2304-5132 2304-5124 reponame:Revista SPOG - Revista Peruana de Ginecología y Obstetricia instname:Sociedad Peruana de Obstetricia y Ginecología instacron:SPOG |
| reponame_str |
Revista SPOG - Revista Peruana de Ginecología y Obstetricia |
| collection |
Revista SPOG - Revista Peruana de Ginecología y Obstetricia |
| instname_str |
Sociedad Peruana de Obstetricia y Ginecología |
| instacron_str |
SPOG |
| institution |
SPOG |
| repository.name.fl_str_mv |
-
|
| repository.mail.fl_str_mv |
mail@mail.com |
| _version_ |
1700655647123570688 |
| spelling |
Survival with radical mastectomy for invasive breast cancerSobrevida con mastectomía radical en cáncer de mama invasorDíaz, JuanSalgado, LuceroRoeder, RafaelTo compare the rates of long-term survival according to various clinical and pathological and therapeutic factors and determine the ten-year survival rates and recurrence after radical mastectomy classic (MRC) and modified radical mastectomy (MRM). MATERIALS AND METHODS: We retrospectively reviewed the medical records of 72 patients with operable invasive breast carcinoma with negative axilla (n = 38) or positive (n = 34), treated with MRC (n = 57) or MRM (n = 15) Belen Hospital, Trujillo, Peru, from 1 January 1966 to December 31, 1995. RESULTS: The mean age was 47.6 ± 9.5 years (range 30-70 years). The average disease duration was 9 months (range 0.3 to 156 months). The most frequent symptoms or signs were present tumor (100%) and breast (37.5%) pain. The ten-year survival rates in patients treated with MRC and MRM, according to the actuarial Kaplan-Meier method were 58% and 54%, respectively (p = NS). There was no significant difference in the rate of ten-year survival between the group of MRC and MRM considering tumor size, number of positive regional nodes, axillary committed, pathological stage and type of treatment. In patients with negative axillary lymph there was a significant improvement in the ten-year survival when treated with MRC with MRM (68% versus 38%, p <0.05). Decadal regional local recurrence rates, and distance MRC group were 21%, 1.8% and 24.6% respectively, while the MRM group decadal rates of local, regional and distant recurrence were 13 , 3 10% and 26%, 7%, respectively (p = NS). CONCLUSIONS: In patients with operable breast carcinoma, the ten-year survival is similar when they are treated with MRC and MRM; however in patients with negative axillary nodes, the ten-year survival is favorably influenced by the MRC.OBJETIVOS: Comparar las tasas de sobrevida a largo plazo según diversos factores clínico-patológicos y terapéuticos y determinar las tasas de sobrevida y recurrencia decenal luego de mastectomía radical clásica (MRC) y mastectomía radical modificada (MRM). MATERIAL Y MÉTODOS: Revisamos retrospectivamente las historias clínicas de 72 pacientes con carcinoma de mama invasor operable con axila negativa (n=38) o positiva (n=34), tratadas con MRC(n=57) o MRM (n=15) en el Hospital Belén, Trujillo, Perú, desde el 1° de enero de 1966 al 31 de diciembre de 1995. RESULTADOS: La edad media fue 47,6 ± 9,5 años (límites, 30 a 70 años). El tiempo medio de enfermedad fue 9 meses (límites, 0,3 a 156 meses). Los síntomas o signos más frecuentes fueron presencia del tumor (100%) y dolor mamario (37,5%). Las tasas de sobrevida decenal en las pacientes tratadas con MRC y MRM, según el método actuarial de Kaplan-Meier, fueron 58% y 54%, respectivamente (p=NS). No hubo diferencia significativa en la tasa de sobrevida decenal entre el grupo de MRC y MRM al considerar el tamaño tumoral, número de ganglios regionales positivos, nivel axilar comprometido, estadio patológico y tipo de tratamiento. En las pacientes con ganglios axilares negativos hubo una mejora significativa en la sobrevida decenal cuando fueron tratadas con MRC que con MRM (68% contra 38%, p < 0,05). Las tasas decenales de recurrencia local, regional y a distancia en el grupo de MRC, fueron 21 %, 1,8% y 24,6%, respectivamente, mientras que el grupo de MRM las tasas decenales de recurrencia local, regional y a distancia fueron 13,3% 10% y 26, 7%, respectivamente (p=NS). CONCLUSIONES: En pacientes con carcinoma de mama operable, la sobrevida decenal es similar cuando éstas son tratadas con MRC y MRM; sin embargo en las pacientes con ganglios axilares negativos, la sobrevida decenal es influida favorablemente por la MRC.Sociedad Peruana de Obstetricia y Ginecología2015-07-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://www.spog.org.pe/web/revista/index.php/RPGO/article/view/137310.31403/rpgo.v45i1373Revista Peruana de Ginecología y Obstetricia; Vol. 45, Núm. 2 (1999); 97-1052304-51322304-5124reponame:Revista SPOG - Revista Peruana de Ginecología y Obstetriciainstname:Sociedad Peruana de Obstetricia y Ginecologíainstacron:SPOGspahttp://www.spog.org.pe/web/revista/index.php/RPGO/article/view/1373/1326info:eu-repo/semantics/openAccess2021-05-24T15:50:17Zmail@mail.com - |
| score |
13.9573765 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).